# ğŸ« Pulmonary Medicine: Dupilumab in COPD With Elevated Eosinophils

#### âœ… True Statements
1. **Dupilumab** is a **monoclonal antibody** that targets **interleukin-4 and interleukin-13 pathways**.  
2. **Dupilumab** reduces **moderate to severe COPD exacerbations**, improves **lung function**, and enhances **quality of life** in patients with **type 2 inflammation** characterized by an **elevated blood eosinophil count**.  
3. **Dupilumab** can be added to the regimen of **long-acting bronchodilators** and **inhaled glucocorticoids** in patients with **chronic bronchitis** and **high eosinophil count**.  
4. **Î±1-Antitrypsin augmentation therapy** may slow **emphysema progression** in **Î±1-antitrypsin deficiency**, but it does **not reduce exacerbations** or **slow FEV1 decline** in patients with COPD unrelated to Î±1-antitrypsin deficiency.  
5. **Oral glucocorticoids** such as **prednisone** should be reserved for **acute exacerbations** of COPD and are not recommended for **long-term daily therapy** because of **adverse effects** and **limited benefit**.  
6. **Theophylline** may improve functional capacity and reduce exacerbations in advanced COPD but is limited by a **narrow therapeutic window** and **frequent toxicity**.  
7. **Dupilumab** is recommended for patients with **poorly controlled COPD** and **elevated eosinophil count**.

#### ğŸ’¬ Extra
2. Type 2 inflammation in COPD is defined by an **eosinophilic phenotype** (blood eosinophils >300 cells/ÂµL).  
4. Î±1-Antitrypsin augmentation therapy is only indicated for patients with **documented Î±1-antitrypsin deficiency** and emphysema.  
5. Long-term oral glucocorticoids increase risks such as **osteoporosis, diabetes, hypertension, and infections**.  
6. Safer alternatives exist, making theophylline a **rarely used** therapy in modern COPD care.  

#### ğŸ·ï¸ Tags
#PulmonaryMedicine #COPD #Biologics #Dupilumab #Eosinophilia #Bronchodilators #Glucocorticoids #Theophylline #Alpha1Antitrypsin  

#### ğŸ“š Reference
Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. *N Engl J Med*. 2023;389:205-14. PMID: 37272521 doi:10.1056/NEJMoa2303951  

#### ğŸ†” Question ID
PMQQQ25001  

#### ğŸ•’ Last Updated
February 2025  

---

#### ğŸ“– Related Text
MKSAP 19: Pulmonary Medicine â€” Airways Disease, Chronic Obstructive Pulmonary Disease, Management of COPD, Pharmacologic Therapy for COPD, Other Agents  

---

### ğŸ“˜ Related Text Derivations

#### âœ… True Statements â€” Other Agents
1. **Macrolide antibiotics** have **anti-inflammatory** and **antimicrobial** effects and may **reduce the frequency of exacerbations** in patients with **severe COPD** and a **history of frequent exacerbations**.  
2. **Mucolytics** and **antitussives** are not routinely used for COPD management but may provide **symptomatic relief** in patients with **significant sputum production**.  
3. **Biologic agents** have focused indications in COPD; **dupilumab** can be added to **long-acting bronchodilators** and **inhaled glucocorticoids** in patients with **chronic bronchitis** and **high eosinophil count**.  
4. **Ensifentrine**, a **phosphodiesterase inhibitor**, improves **lung function** and may **decrease exacerbation frequency**, but it has **not been shown to improve quality of life**, and its role in therapy remains unclear.  

#### ğŸ’¬ Extra
1. The **anti-inflammatory effect** of macrolides (e.g., azithromycin) extends beyond antimicrobial activity.  
2. These agents are **adjunctive options** for selected symptomatic patients but lack evidence for routine use.  
4. Ensifentrineâ€™s long-term clinical significance is still **under investigation**.  

#### ğŸ·ï¸ Tags
#COPD #Macrolides #Mucolytics #Biologics #Dupilumab #Ensifentrine #Exacerbations  
